Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Requests for Inspection Under the Inspection by Accredited Persons Program, 59400-59401 [2011-24582]
Download as PDF
59400
Federal Register / Vol. 76, No. 186 / Monday, September 26, 2011 / Notices
Description: The Administration for
Children and Families (ACF), U.S.
Department of Health and Human
Services is proposing an information
collection activity as part of a study of
responsible fatherhood prisoner reentry
pilot programs. This information
collection will involve discussion of a
range of topics with key informants in
grantee and partner organizations such
as their organizational structure,
program services, populations served,
and specific approaches under the grant
programs, as well as with individuals
who participate, eligible
nonparticipants, and family members
about their-circumstances and
experiences.
Respondents: Semi-structured
discussions will be held with
administrators, managers and staff of
responsible fatherhood prisoner reentry
grant programs and of key partner or
community agencies. Information may
also be collected from participants,
eligible non-participants, and family
members.
ANNUAL BURDEN ESTIMATES
Instrument
Annual
number of
respondents
Number of
responses per
respondent
Average
burden hours
per response
Total
annual burden
hours
Discussion Guides ...........................................................................................
150
1
1
150
jlentini on DSK4TPTVN1PROD with NOTICES
Estimated Total Annual Burden
Hours: 150.
In compliance with the requirements
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
Copies of the proposed collection of
information can be obtained and
comments may be forwarded by writing
to the Administration for Children and
Families, Office of Planning, Research
and Evaluation, 370 L’Enfant
Promenade, SW., Washington, DC
20447, Attn: OPRE Reports Clearance
Officer. E-mail address:
OPREinfocollection@acf.hhs.gov. All
requests should be identified by the title
of the information collection.
The Department specifically requests
comments on (a) Whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
the quality, utility, and clarity of the
information to be collected; and (d)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
other forms of information technology.
Consideration will be given to
comments and suggestions submitted
within 60 days of this publication.
Dated: September 20, 2011.
Steven M. Hanmer,
Reports Clearance Officer.
[FR Doc. 2011–24536 Filed 9–23–11; 8:45 am]
BILLING CODE 4184–35–M
VerDate Mar<15>2010
17:37 Sep 23, 2011
Jkt 223001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
collection of information to OMB for
review and clearance.
Food and Drug Administration
Requests for Inspection Under the
Inspection by Accredited Persons
Program—(OMB Control Number 0910–
0569)—(Extension)
[Docket No. FDA–2011–N–0322]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Requests for
Inspection Under the Inspection by
Accredited Persons Program
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by October 26,
2011.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0569. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
PO 00000
Frm 00022
Fmt 4703
Sfmt 4703
Section 201 of the Medical Device
User Fee and Modernization Act of 2002
(Pub. L. 107–250) amended section 704
of the Federal Food, Drug, and Cosmetic
Act by adding subsection (g) (21 U.S.C.
374(g)). This amendment authorized
FDA to establish a voluntary third-party
inspection program applicable to
manufacturers of class II or class III
medical devices who meet certain
eligibility criteria. In 2007, the program
was modified by the Food and Drug
Administration Amendments Act of
2007 by revising eligibility criteria and
by no longer requiring prior approval by
FDA. To reflect the revisions, FDA
modified the title of the collection of
information and on March 2, 2009,
issued a guidance entitled
‘‘Manufacturer’s Notification of the
Intent to Use an Accredited Person
Under the Accredited Persons
Inspection Program Authorized by
Section 228 of the Food and Drug
Administration Amendments Act of
2007.’’ This guidance supersedes the
Agency’s previous guidance regarding
requests for third-party inspection and
may be found on the Internet at
https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/ucm085187.htm.
This guidance is intended to assist
device establishments in determining
whether they are eligible to participate
in the Accredited Persons (AP) Program
and, if so, how to submit notification of
their intent to use the program. The AP
Program applies to manufacturers who
currently market their medical devices
in the United States and who also
market or plan to market their devices
in foreign countries. Such
E:\FR\FM\26SEN1.SGM
26SEN1
59401
Federal Register / Vol. 76, No. 186 / Monday, September 26, 2011 / Notices
manufacturers may need current
inspections of their establishments to
operate in global commerce.
There are approximately 8,000 foreign
and 10,000 domestic manufacturers of
medical devices. Approximately 5,000
of these firms only manufacture class I
devices and are, therefore, not eligible
for the AP Program. In addition, 40
percent of the domestic firms do not
export devices and therefore are not
eligible to participate in the AP
Program. Further, 10 to 15 percent of the
firms are not eligible due to the results
of their previous inspection. FDA
estimates there are 4,000 domestic
manufacturers and 4,000 foreign
manufacturers that are eligible for
inclusion under the AP Program. Based
on communications with industry, FDA
estimates that on an annual basis
approximately 100 of these
manufacturers may use an AP in any
given year.
In the Federal Register of May 23,
2011 (76 FR 29764), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
21 U.S.C. section
374(g) ...................................................................................
1 There
FOR FURTHER INFORMATION CONTACT:
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0275]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Certification to
Accompany Drug, Biological Product,
and Device Applications or
Submissions (Form FDA 3674)
Food and Drug Administration,
HHS.
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by October 26,
2011.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or e-mailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0616. Also
include the FDA docket number found
SUMMARY:
jlentini on DSK4TPTVN1PROD with NOTICES
1
in brackets in the heading of this
document.
[FR Doc. 2011–24582 Filed 9–23–11; 8:45 am]
ACTION:
100
Total annual
responses
100
Average
burden per
response
15
Total hours
1,500
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: September 20, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
AGENCY:
Number of
responses per
respondent
VerDate Mar<15>2010
17:37 Sep 23, 2011
Jkt 223001
Jonna Capezzuto, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3794,
Jonnalynn.capezzuto@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance. Certification to
Accompany Drug, Biological Product,
and Device Applications or Submissions
(Form FDA 3674)—(OMB Control
Number 0910–0616)—Extension
The information required under
section 402(j)(5)(B) of the Public Health
Service Act (PHS Act) (42 U.S.C.
282(j)(5)(B)) is submitted in the form of
a certification, Form FDA 3674, which
accompanies applications and
submissions currently submitted to FDA
and is already approved by OMB. The
OMB control numbers and expiration
dates for submitting Form FDA 3674
under the following parts are: 21 CFR
parts 312 and 314 (human drugs) are
0910–0014, expiring August 31, 2011,
and 0910–0001, expiring May 31, 2011;
21 CFR parts 312 and 601 (biological
products) are 0910–0014 and 0910–
0338, expiring December 31, 2011; 21
CFR parts 807 and 814 (devices) are
0910–0120, expiring December 31, 2013,
and 0910–0231, expiring December 31,
2013.
Title VIII of the Food and Drug
Administration Amendments Act of
2007 (FDAAA) (Pub. L. 110–85)
amended the PHS Act by adding section
402(j) (42 U.S.C. 282(j)). The provisions
require additional information to be
submitted to the clinical trials data bank
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
(https://ClinicalTrials.gov) 1 previously
established by the National Institutes of
Health (NIH)/National Library of
Medicine, including expanded
information on clinical trials and
information on the results of clinical
trials. The provisions include
responsibilities for FDA as well as
several amendments to the Federal
Food, Drug, and Cosmetic Act (the
FD&C Act).
One provision, section 402(j)(5)(B) of
the PHS Act, requires that a certification
accompany human drug, biological, and
device product submissions made to
FDA. Specifically, at the time of
submission of an application under
sections 505, 515, or 520(m) of the
FD&C Act (21 U.S.C. 355, 360e, or
360j(m)), or under section 351 of the
PHS Act (42 U.S.C. 262), or submission
of a report under section 510(k) of the
FD&C Act (21 U.S.C. 360(k)), such
application or submission must be
accompanied by a certification, Form
FDA 3674, that all applicable
requirements of section 402(j) of the
PHS Act have been met. Where
available, such certification must
include the appropriate National
Clinical Trial (NCT) numbers.
The proposed extension of the
collection of information is necessary to
satisfy the previously mentioned
statutory requirement.
The importance of obtaining these
data relates to adherence to the legal
requirements for submissions to the
clinical trials registry and results data
bank and ensuring that individuals and
organizations submitting applications or
reports to FDA under the listed
1 FDA has verified the Web site addresses
throughout this document, but FDA is not
responsible for any subsequent changes to the Web
sites after this document publishes in the Federal
Register.
E:\FR\FM\26SEN1.SGM
26SEN1
Agencies
[Federal Register Volume 76, Number 186 (Monday, September 26, 2011)]
[Notices]
[Pages 59400-59401]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-24582]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0322]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Requests for
Inspection Under the Inspection by Accredited Persons Program
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by October
26, 2011.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: 202-395-7285, or e-mailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0569.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Requests for Inspection Under the Inspection by Accredited Persons
Program--(OMB Control Number 0910-0569)--(Extension)
Section 201 of the Medical Device User Fee and Modernization Act of
2002 (Pub. L. 107-250) amended section 704 of the Federal Food, Drug,
and Cosmetic Act by adding subsection (g) (21 U.S.C. 374(g)). This
amendment authorized FDA to establish a voluntary third-party
inspection program applicable to manufacturers of class II or class III
medical devices who meet certain eligibility criteria. In 2007, the
program was modified by the Food and Drug Administration Amendments Act
of 2007 by revising eligibility criteria and by no longer requiring
prior approval by FDA. To reflect the revisions, FDA modified the title
of the collection of information and on March 2, 2009, issued a
guidance entitled ``Manufacturer's Notification of the Intent to Use an
Accredited Person Under the Accredited Persons Inspection Program
Authorized by Section 228 of the Food and Drug Administration
Amendments Act of 2007.'' This guidance supersedes the Agency's
previous guidance regarding requests for third-party inspection and may
be found on the Internet at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm085187.htm. This
guidance is intended to assist device establishments in determining
whether they are eligible to participate in the Accredited Persons (AP)
Program and, if so, how to submit notification of their intent to use
the program. The AP Program applies to manufacturers who currently
market their medical devices in the United States and who also market
or plan to market their devices in foreign countries. Such
[[Page 59401]]
manufacturers may need current inspections of their establishments to
operate in global commerce.
There are approximately 8,000 foreign and 10,000 domestic
manufacturers of medical devices. Approximately 5,000 of these firms
only manufacture class I devices and are, therefore, not eligible for
the AP Program. In addition, 40 percent of the domestic firms do not
export devices and therefore are not eligible to participate in the AP
Program. Further, 10 to 15 percent of the firms are not eligible due to
the results of their previous inspection. FDA estimates there are 4,000
domestic manufacturers and 4,000 foreign manufacturers that are
eligible for inclusion under the AP Program. Based on communications
with industry, FDA estimates that on an annual basis approximately 100
of these manufacturers may use an AP in any given year.
In the Federal Register of May 23, 2011 (76 FR 29764), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 U.S.C. section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
374(g).......................... 100 1 100 15 1,500
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: September 20, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-24582 Filed 9-23-11; 8:45 am]
BILLING CODE 4160-01-P